

NEXT OPENING

Cabozantinib 40 mg PO
+
Atezolizumab 1200 mg Q3W

→	Cohort 1	Well-differentiated neuroendocrine tumors of lung origin (WHO grade 1 and 2, typical and atypical carcinoids)	N = 9 + 15 pts
→	Cohort 2	Anaplastic thyroid cancer	N = 9 + 15 pts
→	Cohort 3	Adrenocortical carcinoma	N = 9 + 15 pts
→	Cohort 4	Pheochromocytoma and paraganglioma	N = 9 + 15 pts
→	Cohort 5	Well-differentiated neuroendocrine tumors of gastroenteropancreatic (WHO grade 1 and 2)	N = 9 + 15 pts
→	Cohort 6	Poorly differentiated neuroendocrine tumors (WHO grade 3), excluding small cell lung cancer	N = 9 + 15 pts

Primary endpoint:
Overall Objective
Response Rate (ORR)

**Estimated Primary
Completion Date:** 3Q
2021 (S1), 2023 (S2)